Log In
Print
BCIQ
Print
Print this Print this
 

MDX-1100

  Manage Alerts
Collapse Summary General Information
Company Bristol-Myers Squibb Co.
DescriptionUltiMAb-derived human mAb against chemokine CXC motif ligand 10 (CXCL10; IP-10)
Molecular Target Chemokine CXC motif ligand 10 (CXCL10) (IP-10)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$2,400.0M

$2,400.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today